Rx Health offers an automated care coordination platform, which provides access to third-party apps, devices, and text within digital health.
The organization has moved to expand this offering through its partnership with Wise Therapeutics, and the inclusion of its digital therapeutic, Personal Zen.
Personal Zen is a game-based therapy that uses a cognitive therapy approach known as attention bias modification. The product is delivered through a smartphone device, and is clinically validated to reduce anxiety and improve stress resilience.
The product was launched in 2020, and was the first to be released from Wise Therapeutics. According to the company, the app is designed to be used for between six and twelve minutes per day, several times per week.
After the deal between the two organizations, physicians will be able to prescribe, monitor, educate, and onboard patients to use the app. The digital therapeutic will be available through the Rx Health platform that is digitally embedded in the electronic health record.
As patients use the application, the Rx Health platform will also record the data regarding their manner of engagement.
From the clinician’s side, they will be able to use remote therapeutic monitoring codes, which reimburse practitioners for prescribing and following patients’ use of digital treatment programs.
Richard Strobridge, CEO of Rx Health, outlined that Personal Zen would become one of the over 250 ‘automated care pathways’ that are available through the company’s platform.
Rx Health was launched by Mount Sinai App Lab in 2016, with the aim of simplifying the process for healthcare professionals choosing between the different health and wellness apps that exist.
The company is able to determine the most effective applications through making use of the data available from clinical trials, HIPAA compliance, economic stability of the app creator, and the evidence-based reviews of the app. Extending beyond apps, Rx Health also enables physicians to prescribe multimedia education, wearables, and remote monitoring programs to patients.
For Wise Therapeutics, it is developing a pipeline of digital therapeutics across a number of different indications. ABM-01 is its most progressed development, which is being tested for adult social anxiety disorder and is currently going through clinical trials.
The app is currently in the recruiting stage for a clinical trial, with the trial expected to finish in June 2023, with follow-up of patients for one year following completion.
